Continuum Advisory’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.45K Buy
+13
New +$1.49K ﹤0.01% 1748
2024
Q2
– Sell
-13
Closed -$502 – 1733
2024
Q1
$502 Buy
+13
New +$465 ﹤0.01% 1608

Other funds holding KYMR

Continuum Advisory's KYMR Position: Q3 2026 in Review

Continuum Advisory opened a new position in Kymera Therapeutics (KYMR) in Q3 2026: 13 shares worth $1.45K. The stake represents ﹤0.01% of the portfolio and ranks #1748 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in KYMR as recently as Q1 2024.

Continuum Advisory first reported a position in KYMR in Q1 2024 and has held it in 2 quarters since. 299 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • Continuum Advisory held 13 shares of Kymera Therapeutics worth $1.45K as of Q3 2026.
  • Kymera Therapeutics was a new Continuum Advisory position in Q3 2026.
  • Kymera Therapeutics made up ﹤0.01% of Continuum Advisory's portfolio in Q3 2026, its #1748 holding.
  • Continuum Advisory first reported a position in Kymera Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • 299 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on Continuum Advisory's 13F filing for Q3 2026, filed 13 Nov 2026.